ClinicalTrials.gg
CompletedNCT00174330Updated Jan 27, 2021

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

A Phase 4 interventional study of atorvastatin and amlodipine in Hypertension and Hyperlipidemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing atorvastatin in Hypertension — 1 open to participants now, 2 under way, none of them phase 3. Atorvastatin · Hypertension.

Enrollment
5th of 19
330 · median 88
Started
2005
the only one that year
Phase 4
10 of 19
1 open now
Registered
2nd of 19
by date
Lead sponsor
3 of 19
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 19 studies testing atorvastatin in Hypertension, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 19 studies testing atorvastatin in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing atorvastatin in Hypertension, or all of them as a file.
02

Study summary

To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .

03

Conditions studied

  • Hypertension
  • Hyperlipidemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of both hyperlipidemia and hypertension.

Exclusion criteria

Exclusion Criteria:

  • Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus.
  • Subjects with other atherosclerotic disease.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone

Secondary outcomes

  1. To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone.

07

Study locations

15 sites
  • Pfizer Investigational Site
    Beijing, Beijing 100044, China
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510080, China
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510100, China
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510515, China
  • Pfizer Investigational Site
    Nanjing, Jiangsu 210029, China
  • Pfizer Investigational Site
    Shen Yang, Liaoning 110016, China
  • Pfizer Investigational Site
    Shanghai, Shanghai 200032, China
  • Pfizer Investigational Site
    Hangzhou, Zhejiang 310016, China
  • Pfizer Investigational Site
    Beijing, 100029, China
  • Pfizer Investigational Site
    Beijing, 100083, China
  • Pfizer Investigational Site
    Beijing, China
  • Pfizer Investigational Site
    Shanghai, 200003, China
  • Pfizer Investigational Site
    Shanghai, 200025, China
  • Pfizer Investigational Site
    Shanghai, 200233, China
  • Pfizer Investigational Site
    Tianjin, 300211, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
May 2005
Completion
Feb 2006
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00174330
First posted
Sep 15, 2005
Start date
May 2005
Completion
Feb 2006
Last update
Jan 27, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Amlodipine

Start the discussion